Press Releases Avacta Group Plc

Equities

AVCT

GB00BYYW9G87

Biotechnology & Medical Research

Delayed London S.E. Other stock markets 12:21:42 08/06/2026 BST			5-day change	1st Jan Change
69.30 ^GBX	-3.08%		-6.35%	+19.48%

06-05	Avacta Group raises GBP9 million for bond repayments	AN
06-05	Avacta Therapeutics Raises GBP9 Million from Share Issue	MT

Press Releases

06-01	Avacta presents updated clinical data showing encouraging early efficacy signals for AVA6000 in salivary gland cancers at ASCO 2026	GL
06-01	Avacta presents updated clinical data showing encouraging early efficacy signals for AVA6000 in salivary gland cancers at ASCO 2026	AQ
05-29	Avacta : Annual Report and Accounts for the year ending 31 December 2025	PU
05-19	Unaudited Preliminary Results for the Year Ended December 31, 2025	GL
05-06	Avacta : presents new comparisons of pre\|CISION® payload release vs approved ADCs and AVA6207 dual payload delivery at Science Day 2026	PU
05-06	Avacta presents new comparisons of pre\|CISION® payload release vs approved ADCs and AVA6207 dual payload delivery at Science Day 2026	GL
04-21	Avacta data at AACR 2026 underline favorable profile of AVA6103 and advantages of pre\|CISION® delivery platform	GL
04-14	Avacta CEO Christina Coughlin Named as One of In Vivo's 2026 Rising Leaders	GL
04-08	Avacta : Announces 2026 Science Day Event	PU
03-31	Avacta announces first patient treated in Phase 1 FOCUS-01 trial of FAP-Exd (AVA6103) - a sustained-release pre\|CISION® exatecan peptide drug conjugate	GL
03-27	Avacta : Results of Oversubscribed Placing and Subscription	PU
03-26	Avacta : Proposed Placing via an accelerated bookbuild and Subscription to raise approximately £10 million	PU
03-17	Avacta Announces Preclinical and Translational Presentations of pre\|CISION® Platform Candidates at the 2026 AACR Annual Conference	GL
03-04	Avacta : TD Cowen 46th Annual Healthcare Conference – Presentation slides	PU
03-04	Avacta : Corporate Deck – March 2026	PU
03-03	Avacta : Academy – Episode 2	PU
02-24	Avacta : Research & Development Spotlight Series, Episode 14	PU
02-24	Avacta's pre\|CISION Mechanism for Payload Delivery Shows Key Advantages Compared to an Antibody Drug Conjugate in Innovative AI-Driven Analysis	GL
02-13	Avacta : Academy – Episode 1	PU
02-09	Avacta appoints Francis Wilson as Chief Scientific Officer	GL
02-09	Avacta appoints Francis Wilson as Chief Scientific Officer	AQ
02-03	Avacta Announces Two Key Clinical Updates to its Faridoxorubicin Program	GL
01-21	Avacta Announces U.S. Food and Drug Administration Clearance of the Investigational New Drug (IND) Application for the Second pre\|CISION® Medicine, FAP-Exatecan (AVA6103)	GL
01-20	Avacta Announces Year-end Trading Update	GL
12-18	Avacta : Research & Development Spotlight Series, Episode 13	PU